Showing results (111-120 of 274) with videos related to
Sort By:
Pageof 28
Investigational New Drugs|January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsJoleen Hubbard, Charles Erlichman, David O Toft, et al.Translational Oncology|August 9, 2022
Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders InitiativeOluwadamilola Olaku, Barbara A Conley, S Percy Ivy, et al.Cancer|February 27, 2008
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapyNilofer S Azad, Christina M Annunziata, Seth M Steinberg, et al.Cancer|May 13, 2004
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinomaBen Davidson, Emilyn Alejandro, Vivi Ann Flørenes, et al.Journal of Cellular Physiology|October 10, 2007
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemiaRiccardo Alessandro, Simona Fontana, Margherita Giordano, et al.Journal of Proteome Research|October 16, 2007
Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell linesSimona Fontana, Riccardo Alessandro, Marilisa Barranca, et al.Journal of the National Cancer Institute|March 29, 2020
Moving Forward in Cervical Cancer: Enhancing Susceptibility to DNA Repair Inhibition and Damage, an NCI Clinical Trials Planning Meeting ReportMatthew M Harkenrider, Merry Jennifer Markham, Don S Dizon, et al.Cancer Causes & Control : CCC|March 3, 2018
Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United StatesSarah M Temkin, Elise C Kohn, Lynne Penberthy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2013
Developing standards for breakthrough therapy designation in oncologySandra J Horning, Daniel A Haber, Wendy K D Selig, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2026
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)Aman Chauhan, Heidi L Weiss, Charles Kunos, et al.Pageof 28